Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Elotuzumab Plus PVd Has Antitumor Activity in Heavily Pretreated R/R Myeloma

May 28th 2025

Elotuzumab plus PVd elicited responses in patients with relapsed/refractory multiple myeloma after a median of 3 prior lines of therapy.

NCCN Guidelines Now Recommend Pemivibart for COVID-19 Prevention in B-Cell Lymphomas

May 28th 2025

Updated NCCN Guidelines recommend pemivibart in immunocompromised patients with B-cell lymphomas who are at higher risk of contracting COVID-19.

Health Canada, European Commission Approve Subcutaneous Nivolumab in the Same Solid Tumor Indications as IV Formulation

May 28th 2025

Nivolumab has been approved for subcutaneous use across several adult solid tumor indications that have an existing indication for intravenous use.

Real-World Analysis Informs Future Directions for Evaluating Dostarlimab/Chemotherapy in Advanced Endometrial Cancer

May 28th 2025

Findings from a real-world study confirm the efficacy and safety of dostarlimab plus chemotherapy in advanced endometrial cancer.

Asciminib Shows Early Activity With Multiple TKIs in Chronic Myeloid Leukemia

May 27th 2025

Asciminib plus nilotinib, imatinib, or dasatinib were effective in patients with CML in chronic or accelerated phase.

MZB1 TCR-Like CAR T-Cell Therapy Yields Antitumor Activity in Multiple Myeloma and Waldenström Macroglobulinemia

May 27th 2025

Elena Maroto-Martin, PhD, highlights the mechanism of action and efficacy of MZB1 TCR-like CAR T-cell therapy in multiple myeloma.

Dr Haldar on the Future Directions for Evaluating NeoAg-VAX in Colorectal Cancer

May 27th 2025

S. Daniel Haldar, MD, explains the future directions for evaluating NeoAg-VAX in colorectal and pancreatic cancer.

Talquetamab/Teclistamab Combo Yields Responses With Increased Infection Incidence in Triple Class–Exposed Myeloma

May 26th 2025

Talquetamab plus teclistamab produced responses with a high rate of infections in relapsed/refractory multiple myeloma.

Zanubrutinib Yields High Response Rates in Japanese Patients With CLL/SLL and Waldenström Macroglobulinemia

May 25th 2025

Zanubrutinib showed high response rates and durable responses among Japanese patients with CLL/SLL and Waldenström macroglobulinemia.

Dr Lantsman on Future Directions for Evaluating Dostarlimab/Chemo in Endometrial Cancer

May 23rd 2025

Taliya Lantsman, MD, discusses future research directions for assessing dostarlimab/chemotherapy in endometrial cancer in the real-world setting.

Dr Matrana on the Importance of Combination Therapies in Metastatic RCC

May 23rd 2025

Marc R. Matrana, MD, emphasizes the need for combination therapies for the treatment of patients with advanced or metastatic renal cell carcinoma.

Olutasidenib Displays High Response Rates in IDH1-Mutated AML Arising From a Prior Myeloproliferative Neoplasm

May 22nd 2025

Olutasidenib was effective both as monotherapy and in combination with azacitidine in patients with IDH1-mutated AML arising from an MPN.

Health Canada Approves Osimertinib for Locally Advanced, Unresectable EGFR+ NSCLC After Chemoradiation

May 22nd 2025

Osimertinib, with conditions, has been approved by Health Canada for locally advanced, unresectable NSCLC, harboring EGFR mutations.

FDA Grants Breakthrough Device Designation to EnVisio X1 for Minimally Invasive Surgery in Cancer Care

May 22nd 2025

The FDA granted breakthrough device designation to EnVisio X1 for minimally invasive surgery in cancer care.

Improved Public Awareness and Immunotherapy Drive Down Melanoma Mortality Amid Rising Incidences

May 21st 2025

Vincent Ma, MD, discusses progress in the management of advanced-stage melanoma and the need for primary prevention during Skin Cancer Awareness Month.

Pola-R-CHP Is Associated With Improved 2-Year PFS Rates in Older Untreated DLBCL Population

May 21st 2025

Pola-R-CHP demonstrated clinically meaningful PFS and safety in older patients with previously untreated diffuse large B-cell lymphoma.

Dr Facon on the Rationale for Evaluating Isa-VRd in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

May 20th 2025

Thierry Facon, MD, details the rationale for evaluating Isa-VRd in patients with transplant-ineligible, newly diagnosed multiple myeloma.

The ‘Bar Is High’ to Usurp BCG, but Novel Therapies Could Drive Change in Bladder Cancer Management

May 20th 2025

Bogdana Schmidt, MD, MPH, discussed FDA-approved BCG-refractory treatments and recent shifts in BCG-naive NMIBC management.

Dr Winter on the Role of Treatment History in Richter Transformation

May 19th 2025

Allison Winter, MD, emphasizes the importance of carefully evaluating treatment history in patients with Richter transformation from CLL.

Dr Hunter on the Role of Momelotinib as First-Line Therapy in Myelofibrosis

May 19th 2025

Anthony M. Hunter, MD, discusses the role of momelotinib for the treatment of adult patients with myelofibrosis and moderate to severe anemia.